SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Weng, W.-K. Articles by Levy, R. Search for Related Content PubMed PubMed Citation Articles by Weng, W.-K. Articles by Levy, R. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2001, Vol. 98, No. 5, pp. 1352-1357 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Wen-Kai Weng and Ronald Levy From the Division of Medical Oncology, Department of Internal Medicine, Stanford University School of Medicine, CA. Rituximab is a chimeric monoclonal antibody that targets B-cell-specific antigen CD20 and an effective treatment for B-cell non-Hodgkin lymphoma. Although it is readily used in clinical practice, the exact mechanism of its antitumor effect is unclear. One potential mechanism involves complement-mediated cytotoxicity. It has been shown that rituximab induces complement-mediated cytotoxicity in follicular lymphoma cells in vitro, and complement inhibitors CD55 and CD59 may regulate this process. To determine whether complement inhibitors play a role in regulating the antitumor effect of rituximab, the expression of complement inhibitors CD46, CD55, and CD59 was analyzed in pretreatment tumor cells from 29 rituximab-treated follicular lymphoma patients. Among them, 8 patients achieved complete responses, 11 patients achieved partial responses, and 10 patients showed no or minimal responses to rituximab treatment. Expression of surface CD20, CD46, CD55, and CD59 was determined by 2-color flow cytometry. Although the CD59 level was slightly lower in the complete response group, there was no statistically significant difference in the expression of individual complement inhibitor CD46 (mean channel fluorescence [MCF]: NR, 26.4; PR, 21.9; CR, 29.9), CD55 (MCF: NR, 16.4; PR, 14.9; CR, 23.2), or CD59 (MCF: NR, 41.6; PR, 40.6; CR, 30.6), the combination of any 2 inhibitors, or all 3 on tumor cells from 3 response groups. In addition, there was no difference in the rituximab-induced complement-mediated cytotoxicity in an in vitro assay using tumor cells from 3 response groups. Thus, CD46, CD55, and CD59 expression on pretreatment tumor cells, or their susceptibility to in vitro complement-mediated killing, does not predict clinical outcome after rituximab treatment. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. I. Vega, S. Huerta-Yepez, M. Martinez-Paniagua, B. Martinez-Miguel, R. Hernandez-Pando, C. R. Gonzalez-Bonilla, P. Chinn, N. Hanna, K. Hariharan, A. R. Jazirehi, et al. Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions Clin. Cancer Res., November 1, 2009; 15(21): 6582 - 6594. [Abstract] [Full Text] [PDF] Y. Mishima, N. Sugimura, Y. Matsumoto-Mishima, Y. Terui, K. Takeuchi, S. Asai, D. Ennishi, H. Asai, M. Yokoyama, K. Kojima, et al. An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy Clin. Cancer Res., May 15, 2009; 15(10): 3624 - 3632. [Abstract] [Full Text] [PDF] S. Dalle, S. Dupire, S. Brunet-Manquat, L. Reslan, A. Plesa, and C. Dumontet In vivo Model of Follicular Lymphoma Resistant to Rituximab Clin. Cancer Res., February 1, 2009; 15(3): 851 - 857. [Abstract] [Full Text] [PDF] S. A. Beers, C. H. T. Chan, S. James, R. R. French, K. E. Attfield, C. M. Brennan, A. Ahuja, M. J. Shlomchik, M. S. Cragg, and M. J. Glennie Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation Blood, November 15, 2008; 112(10): 4170 - 4177. [Abstract] [Full Text] [PDF] E. Racila, B. K. Link, W.-K. Weng, T. E. Witzig, S. Ansell, M. J. Maurer, J. Huang, C. Dahle, A. Halwani, R. Levy, et al. A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma Clin. Cancer Res., October 15, 2008; 14(20): 6697 - 6703. [Abstract] [Full Text] [PDF] K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al. Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., October 1, 2008; 26(28): 4587 - 4594. [Abstract] [Full Text] [PDF] X. Zhou, W. Hu, and X. Qin The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy Oncologist, September 1, 2008; 13(9): 954 - 966. [Abstract] [Full Text] [PDF] V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV Blood, August 15, 2008; 112(4): 1205 - 1213. [Abstract] [Full Text] [PDF] C. Meyer zum Buschenfelde, Y. Feuerstacke, K. S. Gotze, K. Scholze, and C. Peschel GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment Cancer Res., July 1, 2008; 68(13): 5414 - 5422. [Abstract] [Full Text] [PDF] S.-Y. Wang, E. Racila, R. P. Taylor, and G. J. Weiner NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement Blood, February 1, 2008; 111(3): 1456 - 1463. [Abstract] [Full Text] [PDF] D. Daniel, B. Yang, D. A. Lawrence, K. Totpal, I. Balter, W. P. Lee, A. Gogineni, M. J. Cole, S. F. Yee, S. Ross, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts Blood, December 1, 2007; 110(12): 4037 - 4046. [Abstract] [Full Text] [PDF] S. E. Strome, E. A. Sausville, and D. Mann A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects Oncologist, September 1, 2007; 12(9): 1084 - 1095. [Abstract] [Full Text] [PDF] R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF] T. van Meerten, R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. Clin. Cancer Res., July 1, 2006; 12(13): 4027 - 4035. [Abstract] [Full Text] [PDF] D. G. Maloney Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines J. Clin. Oncol., September 10, 2005; 23(26): 6421 - 6428. [Abstract] [Full Text] [PDF] N. Zhang, L. A. Khawli, P. Hu, and A. L. Epstein Generation of Rituximab Polymer May Cause Hyper-Cross-linking-Induced Apoptosis in Non-Hodgkin's Lymphomas Clin. Cancer Res., August 15, 2005; 11(16): 5971 - 5980. [Abstract] [Full Text] [PDF] Y. Hamaguchi, J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice J. Immunol., April 1, 2005; 174(7): 4389 - 4399. [Abstract] [Full Text] [PDF] P. Carter and C. F. McDonagh Designer Antibody-Based Therapeutics for Oncology Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 147 - 154. [Full Text] [PDF] S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab J. Clin. Oncol., February 1, 2005; 23(4): 712 - 719. [Abstract] [Full Text] [PDF] J. W. Friedberg, H. Kim, M. McCauley, E. M. Hessel, P. Sims, D. C. Fisher, L. M. Nadler, R. L. Coffman, and A. S. Freedman Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-{alpha}/{beta}-inducible gene expression, without significant toxicity Blood, January 15, 2005; 105(2): 489 - 495. [Abstract] [Full Text] [PDF] S. P. Treon, C. Emmanouilides, E. Kimby, A. Kelliher, F. Preffer, A. R. Branagan, K. C. Anderson, S. R. Frankel, and On behalf the Waldenstrom's Macroglobulinemia Clin Extended rituximab therapy in Waldenstrom's macroglobulinemia Ann. Onc., January 1, 2005; 16(1): 132 - 138. [Abstract] [Full Text] [PDF] J. W. Friedberg Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy Hematology, January 1, 2005; 2005(1): 329 - 334. [Abstract] [Full Text] [PDF] J. P. Leonard Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates Hematology, January 1, 2005; 2005(1): 335 - 339. [Abstract] [Full Text] [PDF] G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny From the bench to the bedside: ways to improve rituximab efficacy Blood, November 1, 2004; 104(9): 2635 - 2642. [Abstract] [Full Text] [PDF] J. L. Teeling, R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. H. I. Parren, C. E. Hack, M. Dechant, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood, September 15, 2004; 104(6): 1793 - 1800. [Abstract] [Full Text] [PDF] A. J. Olszewski and M. L. Grossbard Empowering Targeted Therapy: Lessons from Rituximab Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30. [Abstract] [Full Text] [PDF] S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship Cancer Res., July 1, 2004; 64(13): 4664 - 4669. [Abstract] [Full Text] [PDF] J. Uchida, Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor-dependent Mechanisms during Anti-CD20 Antibody Immunotherapy J. Exp. Med., June 21, 2004; 199(12): 1659 - 1669. [Abstract] [Full Text] [PDF] M. S. Cragg and M. J. Glennie Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents Blood, April 1, 2004; 103(7): 2738 - 2743. [Abstract] [Full Text] [PDF] C. F. Eisenbeis, M. A. Caligiuri, and J. C. Byrd Rituximab: Converging Mechanisms of Action in Non-Hodgkin's Lymphoma? Clin. Cancer Res., December 1, 2003; 9(16): 5810 - 5812. [Full Text] [PDF] W.-K. Weng and R. Levy Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma J. Clin. Oncol., November 1, 2003; 21(21): 3940 - 3947. [Abstract] [Full Text] [PDF] D. Sansonno, V. De Re, G. Lauletta, F. A. Tucci, M. Boiocchi, and F. Dammacco Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 Blood, May 15, 2003; 101(10): 3818 - 3826. [Abstract] [Full Text] [PDF] R. Bannerji, S. Kitada, I. W. Flinn, M. Pearson, D. Young, J. C. Reed, and J. C. Byrd Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance J. Clin. Oncol., April 15, 2003; 21(8): 1466 - 1471. [Abstract] [Full Text] [PDF] O. Manches, G. Lui, L. Chaperot, R. Gressin, J.-P. Molens, M.-C. Jacob, J.-J. Sotto, D. Leroux, J.-C. Bensa, and J. Plumas In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas Blood, February 1, 2003; 101(3): 949 - 954. [Abstract] [Full Text] [PDF] M. S. Cragg, S. M. Morgan, H. T. C. Chan, B. P. Morgan, A. V. Filatov, P. W. M. Johnson, R. R. French, and M. J. Glennie Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Blood, February 1, 2003; 101(3): 1045 - 1052. [Abstract] [Full Text] [PDF] A. D. Kennedy, M. D. Solga, T. A. Schuman, A. W. Chi, M. A. Lindorfer, W. M. Sutherland, P. L. Foley, and R. P. Taylor An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab Blood, February 1, 2003; 101(3): 1071 - 1079. [Abstract] [Full Text] [PDF] M. Dechant, G. Vidarsson, B. Stockmeyer, R. Repp, M. J. Glennie, M. Gramatzki, J. G. J. van de Winkel, and T. Valerius Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing Blood, December 15, 2002; 100(13): 4574 - 4580. [Abstract] [Full Text] [PDF] J. D. Hainsworth, S. Litchy, H. A. Burris III, D. C. Scullin Jr, S. W. Corso, D. A. Yardley, L. Morrissey, and F. A. Greco Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., October 15, 2002; 20(20): 4261 - 4267. [Abstract] [Full Text] [PDF] A. L. Rose, B. E. Smith, and D. G. Maloney Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects Blood, August 13, 2002; 100(5): 1765 - 1773. [Abstract] [Full Text] [PDF] M. A. Dimopoulos, C. Zervas, A. Zomas, C. Kiamouris, N. A. Viniou, V. Grigoraki, C. Karkantaris, C. Mitsouli, D. Gika, J. Christakis, et al. Treatment of Waldenstrom's Macroglobulinemia With Rituximab J. Clin. Oncol., May 1, 2002; 20(9): 2327 - 2333. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020